Relay Therapeutics (RLAY) Free Cash Flow (2019 - 2026)
Relay Therapeutics (RLAY) reported Free Cash Flow of -$51.1 million for Q1 2026, up 30.55% year-over-year from -$39.2 million in Q1 2025, and down 13.92% on a QoQ basis from -$44.9 million in Q4 2025.
Relay Therapeutics (RLAY) has 8 years of Free Cash Flow data on file, last reported at -$51.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 30.55% year-over-year to -$51.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$213.4 million (up 21.73% YoY) and the FY2025 annual result came in at -$235.9 million, up 6.08% from the prior year.
- Free Cash Flow retreated to -$51.1 million in Q1 2026 per RLAY's latest filing, from -$44.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$44.9 million in Q4 2025 and bottomed at -$89.3 million in Q4 2023.
- The 5-year median for Free Cash Flow is -$62.1 million (2025), against an average of -$63.6 million.
- The widest annual swing landed in 2022, when Free Cash Flow sank 211.66%; it then jumped 35.2% in 2024.
- Tracing RLAY's Free Cash Flow over 5 years: stood at -$59.4 million in 2022, then plunged by 50.36% to -$89.3 million in 2023, then jumped by 35.2% to -$57.9 million in 2024, then increased by 22.47% to -$44.9 million in 2025, then dropped by 13.92% to -$51.1 million in 2026.
- Per Business Quant, the three latest RLAY Free Cash Flow figures stand at -$51.1 million (Q1 2026), -$44.9 million (Q4 2025), and -$62.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -51.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.11 Mn |
| Mar 31, 2026 | -51.11 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Jun 30, 2025 | -55.29 Mn |
| Jun 30, 2025 | -55.29 Mn |
| Mar 31, 2025 | -73.59 Mn |
| Mar 31, 2025 | -73.59 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Jun 30, 2024 | -65.84 Mn |
| Jun 30, 2024 | -65.84 Mn |
| Mar 31, 2024 | -52.10 Mn |
| Mar 31, 2024 | -52.10 Mn |
| Dec 31, 2023 | -89.31 Mn |
| Dec 31, 2023 | -89.31 Mn |
| Sep 30, 2023 | -75.99 Mn |
| Sep 30, 2023 | -75.99 Mn |
| Jun 30, 2023 | -70.10 Mn |
| Jun 30, 2023 | -70.10 Mn |
| Mar 31, 2023 | -69.05 Mn |
| Mar 31, 2023 | -69.05 Mn |
| Dec 31, 2022 | -59.40 Mn |
| Dec 31, 2022 | -59.40 Mn |
| Sep 30, 2022 | -68.24 Mn |
| Sep 30, 2022 | -68.24 Mn |
| Jun 30, 2022 | -58.95 Mn |
| Jun 30, 2022 | -58.95 Mn |
| Mar 31, 2022 | -51.97 Mn |
| Mar 31, 2022 | -51.97 Mn |
| Dec 31, 2021 | -40.59 Mn |
| Dec 31, 2021 | -40.59 Mn |
| Sep 30, 2021 | -54.71 Mn |
| Sep 30, 2021 | -54.71 Mn |
| Jun 30, 2021 | -29.12 Mn |
| Jun 30, 2021 | -29.12 Mn |
| Mar 31, 2021 | 46.54 Mn |
| Mar 31, 2021 | 46.54 Mn |
| Dec 31, 2020 | -35.34 Mn |
| Dec 31, 2020 | -35.34 Mn |
| Sep 30, 2020 | -25.58 Mn |
| Sep 30, 2020 | -25.58 Mn |
| Jun 30, 2020 | -21.12 Mn |
| Jun 30, 2020 | -21.12 Mn |
| Mar 31, 2020 | -22.39 Mn |
| Mar 31, 2020 | -22.39 Mn |
| Dec 31, 2019 | -30.74 Mn |
| Dec 31, 2019 | -30.74 Mn |
| Sep 30, 2019 | -16.37 Mn |
| Sep 30, 2019 | -16.37 Mn |